DOCSLIB.ORG

Drug Schedules Regulation B.C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Schedules Regulation B.C Pharmacy Operations and Drug Scheduling Act DRUG SCHEDULES REGULATION B.C. Reg. 9/98 Deposited and effective January 9, 1998 Last amended June 17, 2019 by B.C. Reg. 135/2019 Consolidated Regulations of British Columbia This is an unofficial consolidation. Point in time from June 17, 2019 to January 5, 2020 B.C. Reg. 9/98 (O.C. 35/98), deposited and effective January 9, 1998, is made under the Pharmacy Operations and Drug Scheduling Act, S.B.C. 2003, c. 77, s. 22. This is an unofficial consolidation provided for convenience only. This is not a copy prepared for the purposes of the Evidence Act. This consolidation includes any amendments deposited and in force as of the currency date at the bottom of each page. See the end of this regulation for any amendments deposited but not in force as of the currency date. Any amendments deposited after the currency date are listed in the B.C. Regulations Bulletins. All amendments to this regulation are listed in the Index of B.C. Regulations. Regulations Bulletins and the Index are available online at www.bclaws.ca. See the User Guide for more information about the Consolidated Regulations of British Columbia. The User Guide and the Consolidated Regulations of British Columbia are available online at www.bclaws.ca. Prepared by: Office of Legislative Counsel Ministry of Attorney General Victoria, B.C. Point in time from June 17, 2019 to January 5, 2020 Pharmacy Operations and Drug Scheduling Act DRUG SCHEDULES REGULATION B.C. Reg. 9/98 Contents 1 Alphabetical order 2 Sale of drugs 3 [Repealed] SCHEDULES Alphabetical order 1 (1) The drug schedules are printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia. (2) Each entry is preceded by a code noted as 1, 1A, 2, 3 or 4, in which 1 = Schedule I 1A = Triplicate/Duplicate Prescription Program 2 = Schedule II 3 = Schedule III 4 = Schedule IV. Sale of drugs 2 (1) Drugs listed in Schedules I, IA, II, III and IV must be sold from licensed pharmacies. (2) Unscheduled drugs may be sold from non-pharmacy outlets. (3) The various schedules are differentiated as follows: Schedule I (Prescription): Schedule I drugs require a prescription for sale and are provided to the public by a pharmacist following the diagnosis and professional intervention of a practitioner. The sale is controlled in a regulated environment as defined by provincial pharmacy legislation. Entries followed by a “V” superscript may be sold without having received a prescription if (a) the drug is in a form not suitable for human use, or (b) the main panel of the manufacturer’s inner label and the manufacturer’s outer label carry, in both official languages, the statement “For Veterinary Use Only” or “For Agricultural Use Only” immediately following or preceding the brand name, proper name or common name, in type size not less than one-half as large as the largest type on the label, and the product is sold in the original manufacturer’s container. Schedule IA (Triplicate/Duplicate Prescription Program): Drugs which may be sold by a pharmacist to a practitioner or on the prescription of a practitioner in Last amended June 17, 2019 1 Point in time from June 17, 2019 to January 5, 2020 B.C. Reg. 9/98 PHARMACY OPERATIONS AND DRUG SCHEDULING ACT DRUG SCHEDULES REGULATION Schedules accordance with Bylaw 5 (31) (6) of the bylaws to the Pharmacists, Pharmacy Operations and Drug Scheduling Act. Schedule II (Professional Service Area): Drugs which may be sold by a pharmacist on a non-prescription basis and which must be retained within the Professional Service Area of the pharmacy where there is no public access and no opportunity for patient self-selection. Schedule III (Professional Products Area): Drugs which may be sold by a pharmacist to any person from the self-selection Professional Products Area of a licensed pharmacy. Schedule IV (Prescription by Pharmacist): Drugs which may be prescribed by a pharmacist in accordance with guidelines approved by the Council. Unscheduled (Non-pharmacy Sale): Drugs which may be sold by a non- pharmacist to any person. [am. B.C. Regs. 312/2001; 210/2002.] 3 Repealed. [B.C. Reg. 418/98.] SCHEDULES [am. B.C. Regs. 9/98; 141/98; 418/98; 247/99; 31/2000; 355/2000; 377/2000; 378/2000; 132/2001; 211/2001; 312/2001; 21/2002; 210/2002; 232/2002; 233/2002; 288/2002; 19/2003; 303/2003; 142/2006; 169/2006; 137/2007; 200/2008; 45/2009; 46/2009; 286/2009; 2/2011; 64/2011; 189/2011; 190/2011; 192/2012; 180/2015; 181/2015; 83/2016; 160/2016; 230/2016; 279/2016; 6/2017, s. (b); 137/2018; 261/2018; 9/2019; 135/2019.] 1 Abacavir and its salts 1 Abatacept 1Abciximab 1 Acamprosate and its salts 1 Acarbose and its derivatives 1 Acebutolol and its salts 1 Acepromazine and its saltsV 1 Acetaminophen, when recommended for administration by intravenous injection 3 Acetaminophen (in sustained-release formulations containing greater than 650 mg per unit or in package sizes greater than 50 units) 1 AcetanilideV 2Acetarsol 1 Acetazolamide 1 Acetohexamide 1 Acetylcarbromal 1 Acetylcholine Chloride 2 Acetylcysteine 1 Acetylsalicylic acid and its salts (in oral preparations containing 80 mg or less per dosage unit in containers with more than 24 dosage units per container) 2 Acetylsalicylic acid and its salts (in oral preparations containing 80 mg or less per dosage unit in child-resistant containers with 24 or less dosage units per container or rectal preparations containing 150 mg or less per dosage unit) V Prescription not required if sold for veterinary use, provided that the product is labelled by the manufacturer “for agricultural use only” or “for veterinary use only” 2 Last amended June 17, 2019 Point in time from June 17, 2019 to January 5, 2020 PHARMACY OPERATIONS AND DRUG SCHEDULING ACT B.C. Reg. 9/98 DRUG SCHEDULES REGULATION Schedules 3 Acetylsalicylic acid and its salts (in products intended for oral use by adults in strengths of 81 mg per dosage unit and 650 mg or greater per dosage unit and in rectal preparations containing more than 150 mg per dosage unit) 1 Acitretin and its salts and derivatives 1 Aconiazide and its salts 1 Acyclovir and its salts 1 Adalimumab 1 Adapalene and its salts and derivatives 1 Adefovir and its salts and derivatives 1 Adenosine or its salts when sold or recommended for administration by intravenous injection 2 Adiphene and its salts for parenteral use 1 Adrenocortical hormones and their salts and derivativesV, including but not limited to betamethasone dipropionate, betamethasone phosphate, betamethasone sodium, betamethasone valerate, budesonide, ciclesonide, clobetasone, cortisone, dexamethasone acetate, dexamethasone phosphate, dexamethasone sodium, difluprednate, fludrocortisone acetate, flunisolide, fluticasone furoate, fluticasone propionate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone sodium, methylprednisolone acetate, methylprednisolone, methylprednisolone sodium, methylprednisolone succinate, mometasone furoate, prednisolone acetate, prednisolone phosphate, prednisolone sodium, prednisone, triamcinolone acetonide, triamcinolone hexacetonide (except (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin, (b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other non- prescription medicinal ingredient that provides 1% or less hydrocortisone in preparations for topical use on the skin, (c) clobetasone butyrate, when sold in a concentration of 0.05% in cream preparations for topical use on the skin, (d) fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray for individuals 18 years of age and older), (e) mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per spray for those 12 years of age and older, and (f) triamcinolone acetonide in a nasal spray that delivers 55 mcg per spray for adults and children 12 years of age and older 1 Agalsidase alfa 1 Alatrofloxacin and its salts and derivatives 1 Aldesleukin 1Alefacept 1 Alemtuzumab 1 Alendronic acid and its salts 1 Alfacalcidol 1A Alfentanil 1 Alfuzosin and its salts 1 Aliskiren and its salts 1 Alkyl nitrites 1 Allergy serums 2 Allethrins (pyrethrins) V Prescription not required if sold for veterinary use, provided that the product is labelled by the manufacturer “for agricultural use only” or “for veterinary use only” Last amended June 17, 2019 3 Point in time from June 17, 2019 to January 5, 2020 B.C. Reg. 9/98 PHARMACY OPERATIONS AND DRUG SCHEDULING ACT DRUG SCHEDULES REGULATION Schedules 1 Allopurinol 1 Allylisopropylacetylurea 1 Almotriptan and its salts 3 Aloe vera latex, its extracts and derivatives (except aloin) (dosage forms for systemic use containing more than 300 mg per dosage unit) 1 Alpha-chloralose 1 Alphadolone and its salts 1 Alphaxalone 1 Alprazolam 1 Alteplase and its salts and derivatives 1 Altrenogest 1 Altretamine 3 Aluminum oxide 1 Alverine and its salts (for parenteral use) 1 Amantadine and its salts 1 Ambenonium chloride 1Ambrisentan 1 Amifostine and its salts 1 Amikacin and its salts and derivatives 1 Amiloride and its salts 1 4-Amino-pteroyl aspartic acid and its salts 1 Amino acid solutions (for parenteral use) 1 Aminocaproic acid 1 Aminoglutethimide 1 Aminolevulinic acid and its salts and derivatives 1 Aminophylline 1 Aminopromazine [proquamezine] and its salts 1 Aminopterin
Load more

Recommended publications
  • United States Patent (10) Patent No.: US 8,916,581 B2 Boyd Et Al
    USOO891 6581 B2 (12) United States Patent (10) Patent No.: US 8,916,581 B2 Boyd et al. (45) Date of Patent: *Dec. 23, 2014 (54) (S)-N-METHYLNALTREXONE 4,194,045 A 3, 1980 Adelstein 4,203,920 A 5, 1980 Diamond et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,241,066 A 12, 1980 Kobylecki et al. H OW d Wagoner,goner, Warwick,s NY (US);s 4,311,833.4,277,605 A T.1/1982 1981 NamikoshiBuyniski et etal. al. Suketu P. Sanghvi, Kendall Park, NJ 4.322,426 A 3/1982 Hermann et al. (US); Christopher Verbicky, 4.326,074 A 4, 1982 Diamond et al. Broadalbin, NY (US); Stephen 4.326,075 A 4, 1982 Diamond et al. “. s 4,377.568 A 3/1983 Chopra et al. Andruski, Clifton Park, NY (US) 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1/1984 White et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,430,327 A 2, 1984 Frederickson et al. Tarrytown, NY (US) 4,452,775 A 6/1984 Kent 4,457,907 A 7/1984 Porteret al. (*) Notice: Subject to any disclaimer, the term of this 4,462.839 A 7/1984 McGinley et al. patent is extended or adjusted under 35 4,518.4334,466,968 A 5/19858, 1984 McGinleyBernstein et al. U.S.C. 154(b) by 344 days. 4,533,739 A 8/1985 Pitzele et al. This patent is Subject to a terminal dis- 4,606,9094,556,552 A 12/19858/1986 PorterBechgaard et al.
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Medication Instructions for Allergy Patients
    MEDICATION INSTRUCTIONS FOR ALLERGY PATIENTS Drugs which contain antihistamine or have antihistaminic effects can result in negative reactions to skin testing. As a result, it may not be possible to properly interpret skin test results, and testing may have to be repeated at a later date. While this list is extensive, it is NOT all inclusive (particularly of the various brand names). Discontinue ALL antihistamines including the following medications seven (7) days prior to skin testing (unless longer time specified): Antihistamines – Generic name (Brand name(s)): Cetirizine (Zyrtec, Zyrtec-D) Hydroxyzine (Vistaril, Atarax) Desloratadine (Clarinex) Levocetirizine (Xyzal) Fexofenadine (Allegra, Allegra-D) Loratadine (Claritin, Claritin-D, Alavert) Diphenhydramine (Aleve PM, Benadryl, Bayer P.M., Benylin, Contac P.M., Doans P.M, Excedrin PM, Legatrin P.M.. Nytol, Tylenol Nighttime, Unisom, Zzzquil) Chlorpheniramine (Aller-Chlor, Allerest, Alka Seltzer Plus, Chlor-Trimeton, Comtrex, Contac, Co-Pyronil, Coricidin, CTM, Deconamine, Dristan, Dura-tap, Naldecon, Ornade Spansules, Rondec, Sinutab, Teldrin, Triaminic, Triaminicin, Tylenol Allergy) Azatadine (Optimine, Trinalin) Doxylamine (Nyquil) Brompheniramine (Bromfed, Dimetane, Dimetapp) Meclizine (Antivert) Carbinoxamine (Clistin, Rondec) Pheniramine Clemastine (Tavist) Phenyltoloxamine (Nadecon) Cyclizine (Marezine) Promethazine (Phenergan) Cyprohepatidine (Periactin) (9 days) Pyrilamine (Mepyramine) Dexbrompheniramine (Drixoral) Quinacrine (Atabrine) Dexchlorpheniramine (Extendryl, Polaramine)
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • (Ph OH N N Me O YO O YO
    US 20070265293A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0265293 A1 Boyd et al. (43) Pub. Date: Nov. 15, 2007 (54) (S)-N-METHYLNALTREXONE Publication Classification (76) Inventors: Thomas A. Boyd, Grandview, NY (51) Int. Cl. (US); Howard Wagoner, Warwick, NY A6II 3L/4355 (2006.01) (US); Suketu P. Sanghvi, Kendall Park, A6M II/00 (2006.01) NJ (US); Christopher Verbicky, A6M I5/08 (2006.01) Broadalbin, NY (US); Stephen 39t. 35O C Andruski, Clifton Park, NY (US) (2006.01) A6IP 3L/00 (2006.01) Correspondence Address: St. 4. CR WOLF GREENFIELD & SACKS, P.C. (2006.01) 6OO ATLANTIC AVENUE 3G (i. 308: BOSTON, MA 02210-2206 (US) A6IP 33/02 (2006.01) C07D 489/00 (2006.01) (21) Appl. No.: 11/441,452 (52) U.S. Cl. .............. 514/282; 128/200.23; 128/202.17; (22) Filed: May 25, 2006 546/45 Related U.S. Application Data (57) ABSTRACT This invention relates to S-MNTX, methods of producing (60) Provisional application No. 60/684,570, filed on May S-MNTX, pharmaceutical preparations comprising 25, 2005. S-MNTX and methods for their use. O G M Br Br e (pH OH N N Me O YO O YO OH OH R-MNTX S-MNTX Patent Application Publication Nov. 15, 2007 Sheet 1 of 6 US 2007/0265293 A1 Fig. 1 OH OH Me-N Me-N D / O O -----BBr, O O CHCI NMP, 3 AUTOCLAVE, 70'C OMe OH 1 2 Br OH As GE) G As 69 GOH Me-N ION Me-N -lass O SO EXCHANGE O SO OH OH 3 S-MNTX 1 - OXYCODONE 2 - OXYMORPHONE 3 - ODIDE SALT OF S-MNTX Fig.
    [Show full text]
  • Histamine and Antihistamines Sites of Action Conditions Which Cause Release Aron H
    Learning Objectives I Histamine Pharmacological effects Histamine and Antihistamines Sites of action Conditions which cause release Aron H. Lichtman, Ph.D. Diagnostic uses Associate Professor II Antihistamines acting at the H1 and H2 receptor Pharmacology and Toxicology Pharmacological effects Mechanisms of action Therapeutic uses Side effects and drug interactions Be familiar with the existence of the H3 receptor III Be able to describe the main mechanism of action of cromolyn sodium and its clinical uses Histamine Pharmacology First autacoid to be discovered. (Greek: autos=self; Histamine Formation akos=cure) Synthesized in 1907 Synthesized in mammalian tissues by Demonstrated to be a natural constituent of decarboxylation of the amino acid l-histidine mammalian tissues (1927) Involved in inflammatory and anaphylactic reactions. Local application causes swelling redness, and edema, mimicking a mild inflammatory reaction. Large systemic doses leads to profound vascular changes similar to those seen after shock or anaphylactic origin Histamine Stored in complex with: Heparin Chondroitin Sulfate Eosinophilic Chemotactic Factor Neutrophilic Chemotactic Factor Proteases 1 Conditions That Release Histamine 1. Tissue injury: Any physical or chemical agent that injures tissue, skin or mucosa are particularly sensitive to injury and will cause the immediate release of histamine from mast cells. 2. Allergic reactions: exposure of an antigen to a previously sensitized (exposed) subject can immediately trigger allergic reactions. If sensitized by IgE antibodies attached to their surface membranes will degranulate when exposed to the appropriate antigen and release histamine, ATP and other mediators. 3. Drugs and other foreign compounds: morphine, dextran, antimalarial drugs, dyes, antibiotic bases, alkaloids, amides, quaternary ammonium compounds, enzymes (phospholipase C).
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Proposed Changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (Effective from 01.01.2022)
    Proposed changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (effective from 01.01.2022) SUBSTANCE NAME CURRENT PROPOSED COMMENT STATUS EPSL CATEGORY ACETYLCHOLINESTERASE INHIBITOR Used in the treatment of Edrophonium Controlled Banned myasthenia gravis and Medication Substance has no legitimate use in the treatment of sports horses Used to increase Huperzine A Unlisted Banned alertness and treat Substance myasthenia gravis. The substance has no legitimate use in the treatment of sports horses. AMIDES Palmitoylethanolamid Banned Controlled Used in the treatment of Substance Medication joint pain ANGIOTENSIN CONVERTING ENZYME INHIBITORS Enalapril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Enalaprilat Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Lisinopril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Moexipril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse 1 Perindoprilat Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse ANTIHISTAMINES Antazoline Controlled Banned The substance has no Medication Substance legitimate use in the sports horse Azatadine Controlled Banned The substance has Medication Substance sedative effects
    [Show full text]
  • Part II Summary of Product Characteristics
    Irish Medicines Board Part II Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Optimine Syrup oral solution 500 mcg/5 ml 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml of solution contains azatadine maleate 500 micrograms. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Oral solution. A clear, colourless, blackcurrant flavoured solution. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications For the symptomatic relief of allergic conditions such as hayfever, vasomotor rhinitis, urticaria, pruritus of allergic origin and allergic reactions associated with insect bites and stings. 4.2 Posology and method of adminstration Adults, the elderly and children over the age of 12 years : - 1mg of azatadine maleate (10ml of syrup) in the morning and evening is recommended. In refractory or more severe cases, 2mg (20ml) may be used. Children (6 -12 years): 0.5 - 1.0mg azatadine maleate (5 - 10ml syrup), twice daily. Optimine Syrup may be diluted with syrup BP. Method of administration : Oral. 4.3 Contraindications Hypersensitivity to the active ingredient or any of the other constituents. Monoamine oxidase inhibitors, which are known to intensify or prolong the anticholinergic and sedative action of drugs, should not be used concomitantly with azatadine maleate. Due to the anticholinergic effect of azatadine maleate, the drug should be used with caution in patients with prostatic hypertrophy, urinary retention, glaucoma, stenosing peptic ulcer or pyloroduodenal obstructions. Patients with rare hereditary problems of fructose intolerance should not take this medicine. 4.4 Special warnings and precautions for use None known. ______________________________________________________________________________________________________________________ Date Printed 14/12/2005 CRN 2017838 page number: 1 Irish Medicines Board 4.5 Interaction with other medicinal products and other forms of interaction Patients taking azatadine maleate should be cautioned against ingestion of alcohol.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.248,195 B2 Rariyet Al
    US009248195B2 (12) United States Patent (10) Patent No.: US 9.248,195 B2 Rariyet al. (45) Date of Patent: *Feb. 2, 2016 (54) ABUSE-DETERRENT PHARMACEUTICAL (52) U.S. Cl. COMPOSITIONS OF OPODS AND OTHER CPC ............... A61K 47/46 (2013.01); A61 K9/1617 DRUGS (2013.01); A61 K9/5026 (2013.01); A61 K 31/485 (2013.01); A61K 45/06 (2013.01); (71) Applicant: COLLEGIUM PHARMACEUTICAL, A61K47/12 (2013.01) INC., Canton, MA (US) (58) Field of Classification Search (72) Inventors: Roman V. Rariy, Allston, MA (US); CPC ......... A61K 9/141; A61 K9/148: A61 K9/20: Alison B. Fleming, North Attleboro, MA A61 K9/48: A61 K9/145; A61 K9/16: A61 K (US); Jane Hirsh, Wellesley, MA (US); 9/1617; A61 K9/50: A61 K9/2013: A61 K Alexander M. Klibanov, Boston, MA 9/2077; A61K31/135; A61K31/485 (US) See application file for complete search history. (73) Assignee: Collegium Pharmaceutical, Inc., (56) References Cited Canton, MA (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 2,404,319 A 7, 1946 Shelton U.S.C. 154(b) by 114 days. 3,015,128 A 1/1962 Somerville, Jr. 3,336,200 A 8, 1967 Krause et al. This patent is Subject to a terminal dis 3,773.955 A 11/1973 Pachter et al. claimer. 3,966,940 A 6, 1976 Pachter et al. 3,980,766 A 9, 1976 Shaw et al. (21) Appl. No.: 14/054,513 4,070,494 A 1/1978 Hoffmeister et al.
    [Show full text]
  • Naturopathic Physicians Regulation
    PROPOSED AMENDMENTS – NATUROPATHIC PHYSICIANS REGULATION Health Professions Act NATUROPATHIC PHYSICIANS REGULATION PROPOSED TO REPLACE B.C. REG. 282/2008 Contents 1 Definitions 2 College name 3 Reserved titles 4 Scope of practice 5 Restricted activities 6 Limits or conditions on services and restricted activities 7 Patient relations program 8 Health profession corporations 1 PROPOSED AMENDMENTS – NATUROPATHIC PHYSICIANS REGULATION Definitions 1 In this regulation: "Act" means the Health Professions Act; "compound" means (a) in respect of a drug, to mix with one or more other ingredients, and (b) in respect of a therapeutic diet, to mix two or more ingredients; "dispense" has the same meaning as in the Pharmacy Operations and Drug Scheduling Act, but excludes a sale, as defined in that Act; "drug" means, except in the definition of "substance", a drug (a) specified in Schedule I of the Drug Schedules Regulation, B.C. Reg. 9/98, other than a drug set out in the Schedule of this regulation, or (b) specified in Schedule II of the Drug Schedules Regulation; "enteral instillation" means instillation directly into the gastrointestinal tract; "minor surgery" means a surgical procedure that (a) is performed, for a diagnostic or therapeutic purpose, on a superficial anatomical structure, and (b) does not involve (i) sedation, general anaesthesia or respiratory assistance, or (ii) a material risk to life; "naturopathic medicine" means the health profession in which a person provides the services of prevention, assessment and treatment of an individual's
    [Show full text]